134 related articles for article (PubMed ID: 17982484)
1. Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling.
Zhu JH; Chen R; Yi W; Cantin GT; Fearns C; Yang Y; Yates JR; Lee JD
Oncogene; 2008 Apr; 27(18):2525-31. PubMed ID: 17982484
[TBL] [Abstract][Full Text] [Related]
2. ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers.
Vermeer PD; Bell M; Lee K; Vermeer DW; Wieking BG; Bilal E; Bhanot G; Drapkin RI; Ganesan S; Klingelhutz AJ; Hendriks WJ; Lee JH
PLoS One; 2012; 7(1):e30447. PubMed ID: 22279592
[TBL] [Abstract][Full Text] [Related]
3. PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness.
Hamyeh M; Bernex F; Larive RM; Naldi A; Urbach S; Simony-Lafontaine J; Puech C; Bakhache W; Solassol J; Coopman PJ; Hendriks WJAJ; Freiss G
Theranostics; 2020; 10(3):1016-1032. PubMed ID: 31938048
[TBL] [Abstract][Full Text] [Related]
4. The nonreceptor-type tyrosine phosphatase PTPN13 is a tumor suppressor gene in non-small cell lung cancer.
Scrima M; De Marco C; De Vita F; Fabiani F; Franco R; Pirozzi G; Rocco G; Malanga D; Viglietto G
Am J Pathol; 2012 Mar; 180(3):1202-1214. PubMed ID: 22245727
[TBL] [Abstract][Full Text] [Related]
5. Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway.
Hoover AC; Strand GL; Nowicki PN; Anderson ME; Vermeer PD; Klingelhutz AJ; Bossler AD; Pottala JV; Hendriks WJ; Lee JH
Oncogene; 2009 Nov; 28(45):3960-70. PubMed ID: 19734941
[TBL] [Abstract][Full Text] [Related]
6. PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
Long Q; Sun J; Lv J; Liang Y; Li H; Li X
Exp Cell Res; 2020 Nov; 396(1):112286. PubMed ID: 32919955
[TBL] [Abstract][Full Text] [Related]
7. PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.
Glondu-Lassis M; Dromard M; Lacroix-Triki M; Nirdé P; Puech C; Knani D; Chalbos D; Freiss G
Cancer Res; 2010 Jun; 70(12):5116-26. PubMed ID: 20501847
[TBL] [Abstract][Full Text] [Related]
8. The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma.
Han X; Xue L; Zhou L; Gong L; Zhu S; Yao L; Wang S; Lan M; Li Y; Zhang W
Exp Mol Pathol; 2013 Dec; 95(3):270-5. PubMed ID: 23906871
[TBL] [Abstract][Full Text] [Related]
9. Dual Role of the PTPN13 Tyrosine Phosphatase in Cancer.
Mcheik S; Aptecar L; Coopman P; D'Hondt V; Freiss G
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33322542
[TBL] [Abstract][Full Text] [Related]
10. The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth.
Spanos WC; Hoover A; Harris GF; Wu S; Strand GL; Anderson ME; Klingelhutz AJ; Hendriks W; Bossler AD; Lee JH
J Virol; 2008 Mar; 82(5):2493-500. PubMed ID: 18160445
[TBL] [Abstract][Full Text] [Related]
11. PTPN13/PTPL1: an important regulator of tumor aggressiveness.
Freiss G; Chalbos D
Anticancer Agents Med Chem; 2011 Jan; 11(1):78-88. PubMed ID: 21235435
[TBL] [Abstract][Full Text] [Related]
12. The tyrosine phosphatase PTPN13/FAP-1 links calpain-2, TBI and tau tyrosine phosphorylation.
Wang Y; Hall RA; Lee M; Kamgar-Parsi A; Bi X; Baudry M
Sci Rep; 2017 Sep; 7(1):11771. PubMed ID: 28924170
[TBL] [Abstract][Full Text] [Related]
13. PTEN-PDZ domain interactions: binding of PTEN to PDZ domains of PTPN13.
Sotelo NS; Schepens JT; Valiente M; Hendriks WJ; Pulido R
Methods; 2015 May; 77-78():147-56. PubMed ID: 25448478
[TBL] [Abstract][Full Text] [Related]
14. Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance.
Zhan H; Jiang J; Luo C; Sun Q; Ke A; Sun C; Hu J; Hu Z; Hu B; Zhu K; Fan J; Zhou J; Huang X
Tumour Biol; 2016 Jul; 37(7):9691-8. PubMed ID: 26801674
[TBL] [Abstract][Full Text] [Related]
15. Switching of the substrate specificity of protein tyrosine phosphatase N12 by cyclin-dependent kinase 2 phosphorylation orchestrating 2 oncogenic pathways.
Li H; Yang D; Ning S; Xu Y; Yang F; Yin R; Feng T; Han S; Guo L; Zhang P; Qu W; Guo R; Song C; Xiao P; Zhou C; Xu Z; Sun JP; Yu X
FASEB J; 2018 Jan; 32(1):73-82. PubMed ID: 28842430
[TBL] [Abstract][Full Text] [Related]
16. Potential role of protein tyrosine phosphatase nonreceptor type 13 in the control of oocyte meiotic maturation.
Nedachi T; Conti M
Development; 2004 Oct; 131(20):4987-98. PubMed ID: 15371306
[TBL] [Abstract][Full Text] [Related]
17. FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion.
Benlimame N; He Q; Jie S; Xiao D; Xu YJ; Loignon M; Schlaepfer DD; Alaoui-Jamali MA
J Cell Biol; 2005 Nov; 171(3):505-16. PubMed ID: 16275754
[TBL] [Abstract][Full Text] [Related]
18. Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells.
Ludyga N; Anastasov N; Rosemann M; Seiler J; Lohmann N; Braselmann H; Mengele K; Schmitt M; Höfler H; Aubele M
Mol Cancer Res; 2013 Apr; 11(4):381-92. PubMed ID: 23364537
[TBL] [Abstract][Full Text] [Related]
19. The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation.
Dromard M; Bompard G; Glondu-Lassis M; Puech C; Chalbos D; Freiss G
Cancer Res; 2007 Jul; 67(14):6806-13. PubMed ID: 17638892
[TBL] [Abstract][Full Text] [Related]
20. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Wang SE; Narasanna A; Perez-Torres M; Xiang B; Wu FY; Yang S; Carpenter G; Gazdar AF; Muthuswamy SK; Arteaga CL
Cancer Cell; 2006 Jul; 10(1):25-38. PubMed ID: 16843263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
